Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
CA 2508228 C · Owner: Hermanson, Gary G. · Inventors: Geall, Andrew J.; Hermanson, Gary G.; Wloch, Mary Kopke
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens in , which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include but are not limited to pp65, glycoprotein B (gB) IE1, and fragments, variants , or derivatives of either of these antigens. In certain embodiments sequences , have been deleted, e.g. the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 19, 2003 and granted December 17, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 19, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 19, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.